Brief Title: Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

PRIMARY OUTCOMES

Primary Outcome 1 - Measure:

Primary Outcome 1 - Timeframe: N/A

CONDITION

• Advanced Urothelial Carcinoma
• Locally Advanced Urothelial Carcinoma
• Metastatic Urothelial Carcinoma
• Refractory Urothelial Carcinoma

ELIGIBILITY

Inclusion Criteria:
* Pathologically confirmed locally advanced or metastatic urothelial carcinoma by histology

- * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1

- * Not eligible to receive cisplatin-based chemotherapy due to renal dysfunction (defined as creatinine clearance [CrCl] =< 60 mL/min), > grade 2 peripheral neuropathy, or ototoxicity (defined as >= grade 2 hearing loss); OR unwillingness of patient to receive cisplatin; OR progressed on one platinum-based chemotherapy regimen for advanced disease

- * May have had neoadjuvant or adjuvant platinum-based chemotherapy or intravesical therapy in the past

- * >= 18 years of age

- * Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2

- * Life expectancy >= 3 months

- * Absolute neutrophil count (ANC) >= 1 × 10^9/L

- * Platelet count >= 75 × 10^9/L (patients for whom <50% of bone marrow nucleated cells are plasma cells) or >= 50,000/mm3 (patients for whom >= 50% of bone marrow nucleated cells are plasma cells)

- * Hemoglobin >= 9 g/dL (may have been transfused)

- * Total bilirubin level =< 1.5 x the upper limit of normal (ULN) range (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 x ULN) - * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN, or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver) - * Creatinine clearance >= 30 mL/min by Cockcroft-Gault formula

- * Subjects with active hepatitis B virus (Hep B) are allowed if antiviral therapy for hepatitis B has been given for > 8 weeks and viral load is < 100 IU/mL prior to first dose of trial treatment. Subjects with untreated hepatitis C virus (HCV) are allowed. Subjects with human immunodeficiency virus (HIV) who have CD4+ T-cell counts >= 350 cells/uL and no history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections in the last year are allowed

- * Willingness to undergo mandatory pre-treatment biopsy (unless there is adequate archival tumor specimen available for PD-L1 IHC evaluation)

- * Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy). Or, female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first study drug administration

- * Male and female subjects who are of reproductive potential must agree to use highly effective method of birth control (e.g., implants, injectables, birth control pills with two hormones, intrauterine devices [IUDs], complete abstinence or sterilized partner, and female sterilization) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 4 months after the last dose of study drug

- * Ability to understand and willingness to sign an informed consent form

- * Ability to adhere to the study visit schedule and other protocol requirements

- * Must be able to swallow study drug
Exclusion Criteria:
* Receiving radiation =< 14 days prior to enrollment to the site of selected target lesions - * Systemic therapy for cancer =< 21 days prior to enrollment - * Autoimmune disorder requiring active therapy as defined by corticosteroids at a dose >= 10 mg oral prednisone or the equivalent or requiring chronic immunosuppressive therapy

- * Use of corticosteroids =< 14 days prior to enrollment at a dose of >= 10 mg oral prednisone or the equivalent per day

- * Received immune checkpoint inhibitor therapy (anti-PD-1, anti-PD-L1, or anti-CTLA4 directed therapy) on a prior clinical trial

- * Has received selinexor or another XPO1 inhibitor previously

- * Any active gastrointestinal dysfunction that could interfere with absorption of study treatment in the opinion of the investigator

- * Pregnant or lactating women

- * Any condition that would prohibit the understanding or rendering of informed consent

- * Any condition including additional malignancies, laboratory abnormalities, or psychiatric illness that in the opinion of the investigator would interfere with the patient's safety or compliance while on trial

- * Severe infection that in the opinion of the investigator would interfere with patient safety or compliance on trial within 4 weeks prior to enrollment

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Mamta Parikh

Role: Principal Investigator

Affiliation: University of California, Davis

Overall Contact

Name: N/A

Phone: N/A

Email: N/A

LOCATION